NOVEL LIPID KINASE

Abstract: The invention relate to a novel human class II PI3-kinase and in particular the sequence of the isolated nucleic acid molecule and the encoded amino acid sequence. The novel human PI3-kinase is termed PI3K-C2 alpha and has unique biochemical properties that characterise and distinguish it from known PI3-kinases. These include, amongst other things, resistance to the PI3-kinase inhibitors Wortmannin and LY294000, the lack of a p85 binding site, a divergent amino terminus and the absence of a polyproline motif which is typical of known type II PI3-kinases.

Description: Novel Lipid Kinase The invention relates to a novel class II PI3 kinase, termed PI3K-C2 , and in particular the isolation thereof having regard to its relevant sequence structure and/or biochemical characteristics; means used in the isolation or production thereof; antibodies adapted to bind thereto; and assay kits relating thereto. Phosphoinositides have been implicated in a variety of cellular processes as diverse as vacuolar protein sorting (1,2), cytoskeletal remodelling (3) and mediating intracellular signalling events through which growth factors, hormones and neurotransmitters exert their physiological effects on cellular activity, proliferation and differentiation (4,5,6). Recently a family of proteins have been cloned and characterised and shown to be enzymes catalysing the addition of phosphate to inositol. Eukaryotic cells contain a variety of inositol derivatives phosphorylated to different extents. PtdIns(3)P is constitutively present in eukaryotic cells and its levels are constant upon extracellular stimulation. PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 (7,8) are virtually absent in resting cells but are rapidly induced upon stimulation with a variety of ligands. The enzymes catalysing these reactions are phosphoinositide lipid kinases (hereinafter called PI3 kinases). A brief overview of the current data in relation to PI3 kinases classifies these enzymes into three distinct groups being designated to an individual class by their in vitro substrate specificity, biochemical characteristics and, in examples where a definitive function has been assigned, the nature of the biochemical activity regulated by the specific kinase. PI3 kinase class 1 polypeptides have a broad spectrum activity, phosphorylating inositol lipids Ptdlns, PtdIns(4)P and Ptdlns(4, 5)P 2 . Class I kinases are subdivided into Class IA and IB. Class IA polypeptides include pl lOα (9), pl lθβ (lθ) and pl lθδ (l l) which interact physically with the adaptor sub-unit protein p85. Moreover, pi 10a and pi 00 have a broad distribution in terms of expression pattern, pi lOδ expression seems to be restricted to white blood cells. Class IB includes pl lOγ (12) which functions independently of p85. Although each of these Class 1 kinases catalyse phosphate addition to inositol lipid, the mechanism via which these enzymes are activated and regulated is achieved by different molecular mechanisms. Class II PI3 kinases have a restricted substrate specificity phosphorylating Ptdlns and PtdIns(4)P but not Ptdlns(4,5) P 2 . Each of the kinases of this class are characterised by a conserved C2 domain in the carboxyl terminal region of the protein. The presence of conserved motifs within the C2 domain indicates that this region may confer regulation via calcium and/or phospholipid. A comparison of the murine and Drosophila class II kinases mpl70 and PI3K_68D respectively reveals a high degree of homology in the kinase domain of these proteins. Significant divergence occurs at the amino terminal regions of these polypeptides suggesting that adaptor proteins interacting with these variable domains may regulate kinase activity. Class II PI3 kinases do not interact with p85. The third class of PI3 kinase, class III PI3 Kinase, is related to the S.cerevisiae gene Vps34 (1). This kinase was originally isolated as a gene involved in regulating vesicle mediated membrane-trafficking in yeast. The human homologue of Vps34 is complexed with a ser/thr kinase called Vpsl5p (14,15). Of the three classes of PI3 kinase this has the most restricted substrate specificity being strictly limited to Ptdlns. A novel human class II PI3 kinase is herein described and termed human PI3K- C2α. It is characterised as a class II kinase due to the presence of a conserved C2 domain found in murine and Drosophila class II PI3 kinases (Fig. 2), its apparent lack of a p85 binding site and a substrate specificity limited to Ptdlns and Ptdlns (4) P (Fig. 4). The polypeptide is unique in that this is the first human class II kinase to be described. It has significant divergence in the amino terminal region of the protein when compared to the mouse homologue of human PI3K-C2α (16). It is also, surprisingly, the first PI3 kinase to be isolated that has resistance to PI3 kinase inhibitors Wortmannin and LY294002 (Fig. 5). The use of selected inhibitors has proved extremely useful in analysing intracellular signal transduction cascades. Inhibitors used at low concentrations probably result in the modification of a single protein's function thereby allowing the dissection of single transduction pathways. A good example of this is the use of Pertussis toxin which is a cell permeant agent (17). The agent undergoes endocytosis into intact cells and results in the ADP-ribosylation of specific GTP -binding or G-proteins. This modification uncouples these G- proteins from their receptors therefore interfering with the cell's response to receptor stimuli. Wortmannin is another cell permeant inhibitor (18,19). It is a fungal metabolite and has been shown to have in vivo anti-inflammatory or immunosuppressive effects in animal models. Wortmannin was first shown to inhibit cellular responses to receptor stimulation in neutrophils. The drug inhibited the respiratory burst induced by ligands such as N-formyl-Met-Leu- Phe,(fMLP),C5a,leukotriene B4 or platelet-activating factors. Importantly, Wortmannin failed to inhibit cellular response to TPA suggesting differential responses to the drug. In particular, the fact that the stimulation of calcium mobilising receptors is resistant to Wortmannin suggests that intracellular signalling initiated by these receptors is controlled by a quite separate kinase cascade. The identification of PI3 kinases as the target for Wortmannin came from in vitro metabolic labelling of guinea pig neutrophils with 32 P to monitor the uptake of phosphate into phospholipids in the presence of specific kinase inhibitors (20). In control experiments stimulation of fMLP receptors resulted in 32 P labelling of phosphatidic acid and PtdIns(3,4,5)P 3 . The presence of Pertussis toxin had no effect on the phosphorylation of these phospholipids. However, pre-incubation of leucocytes with Wortmannin resulted in inhibition of 32 P incorporation into only PtdIns(3,4,5)P 3 . Since this is the product of PI3 kinase catalysed reactions it seems likely that Wortmannin was specifically targeting PI3 kinase. Subsequently, Wortmannin has been shown to block a number of physiological processes including many insulin stimulated actions that would result in enhanced glucose utilisation (21). Wortmannin has proved to be an effective inhibitor of mammalian PI3 kinases. To date, no human PI3 kinase has been cloned and shown to be resistant to this agent. The isolation and sequencing of an as yet unidentified human PI3 kinase that has significant homology to previously identified murine and Drosophila class II kinases is described (16,22,23). Comparison of the optimal alignment of these aforementioned proteins shows the human protein to be 32.5% homologous with sequences of the Drosophila PI3K_68D and cpk proteins and 90.8% and 90.2% with the murine proteins mpl70 and mcpk, Figure 2. The carboxyl terminal region of the aforementioned proteins have increased homology due to the presence of a conserved C2 domain. This domain is characterised by the presence of motifs likely to be involved in the modulation of kinase activity by calcium and/or phospholipid. The amino terminal region of human PI3K-C2α is extended by 176 amino acid residues which are lacking in the murine sequence of mpl70. The murine mcpk protein has a 28 amino acid residue deletion in this region that is absent from human PI3K-C2α and a mpl70. This divergence in sequence may be explained by the presence of the unique binding sites for adaptor proteins that regulate kinase activity. This is supported by the lack of an apparent p85 binding motif. Furthermore, immunofluoresence experiments using a monoclonal antibody to the amino terminal glu-tag of PI3K-C2α reveals a punctate cytoplasmic distribution in Cos cells expressing the recombinant glu-tagged PI3K-C2α protein, figure 9 . Moreover subcellular fractionation of Monkey Kidney Cos cells shows that epitope tagged PI3K-C2α is tightly associated with phospholipid containing membranes. The nature of this interaction is currently unknown but may be mediated via phospholipid interaction with the C2 domain or alternatively through binding to an additional polypeptide localised to microsomes and plasma membranes. The recombinantly produced PI3K-2Cα kinase shows increased resistance to the general PI3 kinase inhibitors Wortmannin and LY294002, (Fig. 5) To date, all cloned human PI3 kinases have been found to be sensitive to these inhibitors. Studies of the Wortmannin sensitive class I PI3 kinase pi 10a identifies residue lys-802 as being the site of Wortmannin covalent inactivation of kinase activity, a residue near or at the active site and involved in phosphate transfer. This residue is present in all PI3 kinase family members and also in PI3K-2Cα, therefore the resistance to Wortmannin by PI3K-2Cα is not apparent. Additionally it will be apparent that alternate methods for use in modulating the activity of PI3K-2Cα exists. For example, having regard to the sequence data provided herein it is possible to provide antisense material which prevents the expression of PI3K-2Cα. As mentioned above, the invention embraces antisense oligonucleotides that selectively bind to a nucleic acid molecule encoding a PI3K-2Cα protein, to decrease transcription and/or translation of PI3K-2Cα genes. This is desirable in virtually any medical condition wherein a reduction in PI3K-2Cα gene product expression is desirable, including to reduce any aspect of a tumor cell phenotype attributable to PI3K-2Cα gene expression. Antisense molecules, in this manner, can be used to slow down or arrest such aspects of a tumor cell phenotype. As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon the DNA sequence presented in Figure 1 or upon allelic or homologous genomic and/or DNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 7 (Wagner et al., Nature Biotechnology 14:840-844, 1996) and. more preferably, at least 15 consecutive bases which are complementary to the target. Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3 '-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., Cell Mol. Neurobiol. 14(5):439-457. 1994) and at which proteins are not expected to bind. Finally, although Figure 1 discloses cDNA sequence, one of ordinary skill in the art may easily derive the genomic DNA corresponding to the cDNA of Figure 1. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to Figure 1. Similarly, antisense to allelic or homologous DNAs and genomic DNAs are enabled without undue experimentation. In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester intemucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors. In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness. The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic intemucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic intemucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, phosphate triesters, acetamidates, peptides, and carboxymethyl esters. The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-0-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. Modified oligonucleotides also can include base analogs such as C-5 propyne modified bases (Wagner et al., Nature Biotechnology 14:840-844, 1996). The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding PI3K-C2α proteins, together with pharmaceutically acceptable carriers. Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art. It follows from the foregoing description that it is an object of this invention to isolate the nucleic acid sequence and derived amino acid sequence of the first human class II PI3 kinase. It is a further object of this invention to recombinantly manufacture human PI3K-C2α kinase. It is a further object of this invention to use computer assisted three dimensional reconstruction of human PI3K-C2α kinase protein to facilitate the identification of agonists or antagonists of PI3K-C2α. It is a yet further object to use said three dimensional reconstruction to design ligands that may modulate the biochemical activity of human PI3-C2αkinase. It is yet a further object of this invention to manufacture an antibody, preferably monoclonal, to PI3K-C2α, and more preferably further still to manufacture a humanised antibody to PI3K-C2α. It is yet a further object of this invention that the monoclonal antibody be specific to class II PI3 kinases. It is yet a further object of this invention to provide an assay kit for use in identifying said protein. According to the first aspect of the invention there is provided the isolated nucleic acid molecule and/or corresponding protein of human PI3K-C2α as shown in Figure 1, including any deletions, additions or substitutions, or a complementary sequence thereto. In a preferred embodiment of the invention said complementary sequence binds to said nucleic acid sequence under stringent conditions. Preferably, these conditions include 0.5M sodium phosphate, pH7.2, 7% SDS, ImM EDTA at 65°C. In yet a further preferred embodiment of the invention said deletions, additions or substitutions do not alter the function of the protein or indeed do not alter the function in a deleterious manner thus, in one example, a nucleic acid molecule may be provided that binds to the relevant gene to prevent expression of P13K- C2α. In yet a further preferred embodiment of the invention said deletions, additions or substitutions do alter the function of the protein. Thus, in one example, a mutation in P13K-C2α could produce a dominant negative mutation that results in the inactivation of endogenous P 13K-C2α in transfected or transformed cells. According to a second aspect of the invention there is provided an antibody, or at least an effective part thereof, which binds at least with a selective part of said human PI3K-C2α. Ideally said effective part comprises FAb fragments. Ideally said antibody is polyclonal or monoclonal and ideally further still said antibody is specific to class II PI3 Kinases. Ideally said antibody is humanised by recombinant methods to contain the variable region of said antibody with an invariant or constant region of a human antibody. Ideally said antibody is provided with a marker including a conventional label or tag, for example a radioactive and/or fluorescent and/or epitope label or tag. More ideally still said humanised monoclonal antibody to class II PI3- kinases is produced as a fusion polypeptide in an expression vector suitably adapted for transfection or transformation of prokaryotic or eukaryotic cells. According to a yet further aspect of the invention there is provided a construct including all, or part of, the said nucleic acid molecule of the invention. In a preferred embodiment of the invention said construct is adapted to be a cloning vehicle for human PI3K-C2α. In a preferred embodiment of the invention said cloning vehicle may be used for expression of the protein sequence of human PI3K-C2α in transformed or transfected prokaryotic and eukaryotic cells. Preferably said cloning vehicle is adapted for use in E.coli, mammalian, insect, amphibian or fungal cells. In a preferred embodiment of the invention said construct includes nucleic acid encoding at least a part of human PI3K-C2α which is functionally linked to a promoter so as to provide for either constitutive or inducible expression of human PI3K-C2α kinase. Preferably further still said construct is adapted for cell/tissue specific expression of PI3K-C2α. According to a yet further aspect of the invention there is provided cells transformed or transfected with the cloning vehicle of the invention and so including the nucleic acid sequence molecule encoding human PI3K-C2α or a part thereof. According to a yet further aspect of the invention there is provided recombinantly manufactured human PI3K-C2α. According to a yet further aspect of the invention there is provided human PI3K-C2α kinases or a fraction thereof, which is characterised by insensitivity to the PI3 kinase(s) inhibitor Wortmannin and/or LY294002. In a further preferred embodiment of this aspect of the invention said protein is also, or alternatively, characterised by the absence of a p85 binding site. In a further preferred embodiment of this aspect of the invention said protein is also, or alternatively, characterised by the absence of a type II polyproline motif present in Drosophilia P13K_68D and cpk. In a yet a further preferred embodiment of this aspect of the invention said protein is also, or alternatively, characterised by divergent amino terminal region when compared to other class II PI3 kinases. In a yet a further preferred embodiment of this aspect of the invention said protein is characterised by a molecular weight of 190Kda. In yet a further preferred embodiment of this aspect of the invention said protein is also, or alternatively, characterised by an in vitro substrate specificity that is restricted to Ptdlns, PtdIns(4)P or at least Ptdlns, PtdIns(4)P. In any of the above embodiments of the invention said fraction ideally comprises the full length amino acid sequence or truncations thereof. According to a further aspect of the invention there is provided the isolated genomic DNA and/or cDNA of human PI3K-C2α kinase according to any previous aspect of the invention. According to a yet further aspect of the invention there is provided a process for the isolation of human PI3K-C2α kinase which process includes a PCR reaction. In a preferred process of the invention said PCR reaction comprises use of at least two primers adapted to bind to at least one selected part of nucleic acid of human PI3K-C2α; and further said process also comprises the provision of conditions for amplifying at least one selected part of said nucleic acid using said primers; and further, following amplification, said process comprises the purification of the amplified product(s); and, optionally, isolation of at least one amplified fragment. In a preferred process of the invention said primers are designed to selectively bind to the nucleic acid of class II kinases and ideally class II human kinases. In yet a further preferred embodiment of the invention said primers are as follows: sense 5'GGNGA T/C GA T/C T/C T A/G CGNCA A/G GA3' antisense 5'A/G AA A/G TGICC A/G AA A/G TC A/G/T AT A/G TG A/G TG A/G AA3' In yet a further preferred embodiment of the invention said primers include any one or more deletions, additions or substitutions which do not deleteriously affect the functional effectiveness of the primers. According to a yet further aspect of the invention there is provided the use of any one of more of the aforementioned primers to isolate class II PI3 kinases and ideally human PI3K-C2α. According to a yet further aspect of the invention there is provided the use of any one or more of the aforementioned primers to isolate human PI3 kinases and ideally human PI3K-C2α. According to a yet further aspect of the invention there is provided an agent which is adapted to interact with the amino terminal region, or any part thereof, of human PI3K-C2α kinase. According to a yet further aspect of the invention there is provided an assay kit for identifying human PI3K-C2α either intracellularly or in a cellular extract. In a preferred embodiment of the invention said assay kit is a diagnostic kit. Preferably said assay kit, or said diagnostic kit makes use of any one or more of the following techniques: western blotting; immunoprecipitation; immunofluorescence on whole cells or tissue sections; or quantitative ELISA reactions. According to a yet further aspect of the invention there is provided a method for identifying agonists or antagonists effective at enhancing or blocking the activity of the polypeptide of the invention which comprises screening candidate molecules for such activity using the polypeptide, or fragments thereof the invention. Ideally, screening may involve artificial techniques such as computer-aided techniques or conventional laboratory techniques. Alternatively, the method of the invention may involve competitive binding assays in order to identify agents that selectively and ideally irreversibly bind to the polypeptide of the invention. According to a yet further aspect of the invention there is provided a pharmaceutical or veterinary composition comprising an agent effective at enhancing or blocking the activity of the polypeptide of the invention which has been formulated for pharmaceutical or veterinary use and which optionally also includes a dilutant, carrier or excipient and/or is in unit dosage form. According to a yet further aspect of the invention there is provided antisense oligonucleotide or a modified antisense oligonucleotide as hereindescribed adapted to hybridise to at least part of the nucleic acid molecule shown in Figure 1. Thus, in general terms the invention describes the nucleic acid sequence and derived amino acid sequence of a novel human class II PI3 kinase, human PI3K-C2α, which has novel features in relation to sequence, biochemistry and responses to well characterised inhibitors of PI3 kinases. An embodiment of the invention will now be described, by example only, and with reference to the following figures, materials and methods wherein; Figure 1 represents the complete cDNA sequence and amino acid sequence of PI3K-C2α; Figure2 shows a comparison of the conserved domains found in type II PI3 kinases and in particular the kinase domains and C2 - domains; Figure 3 represents a northern blot the distribution of mRNA encoding PI3K- C2α in various tissues; Figure 4 represents the in vitro substrate specificity of PI3K-C2α in the presence of Mg 2+ and Mn 2+ , pi 10a is included as a positive control; Figure 5 represents the resistance of recombinant PI3K-C2α to the PI3 -kinase inhibitors Wortmannin and LY 294002, ( pi 10a = •, recombinant PI3K-C2α = o ); Figure 6 is a diagrammatic representation of the sub-cellular fractionation of Cos 7 cells into various membrane fractions; Figure 7 represents a western blot of cell lysates prepared from various cell- lines and probed with antisera to PI3K-C2α; Figure 8 represents a western blot of sub-cellular fractions prepared from Cos 7 cells and probed with antisera to PI3K-C2α; and Figure 9 represents an immunofluoresence image of Cos7 cells expressing recombinant glu-tagged PI3K-C2 . Materials and Methods Identification of PI3K-C2α cDNA Poly A+ RNA was isolated from U937 cells using oligo(dT) cellulose (Stratagene) and used to synthesise first strand cDNA with AMV reverse transcriptase (Pharmacia). PCR reactions were then performed using Taq DNA polymerase (Life Technologies), first strand cDNA, 4mM Mg2+ and lμ M primers. The nucleotide sequences of the primers used were sense - GGNGA T/C GA T/C T/C T A/G CGNCA A/G GA (GDDLRQD/E) and antisense - A/G AA A/G TGICC A/G AA A/G TC A/G/T AT A/G TG A/G TG A/G AA (FHIDFGHF). To facilitate subsequent cloning, an EcoRI restriction site was incorporated into the 5'end of each primer. The conditions used were 30 cycles of 94°C for 30s, 56°C for 30s, and 72°C for 30s. After sub cloning into a Bluescript-SK vector, individual clones were selected and sequenced (ABI). Isolation of PI3K-C2α cDNA The PCR fragment was excised from the vector, labelled with 32 P dCTP using random primers (Amersham) and used to screen a 1 λzap U937 cDNA library (Stratagene). Approximately 3x10 6 plaques were plated and transferred onto Hybond-N filters (Amersham). These were hybridised with the probe for 16 hours at 65°C in 0.5M sodium phosphate ρH7.2, 7% SDS and ImM EDTA. After this time, the filters were washed twice with 0.5x SSC/0.1% SDS for 20 minutes at 60°C and positive clones identified by autoradiography. After three rounds of screening, clones were plaque purified and the cDNA insert in Bluescript-SK was rescued using ExAssist helper phage (Stratagene). The nucleotide sequence of the longest clone was determined using both Taq di deoxy terminator cycle sequencing (ABI) and di deoxy chain termination using T7 DNA polymerase and a 35 S thio dATP (Lark Sequencing Technologies). The 5' end of the cDNA was obtained by rapid amplification of cDNA ends. cDNA was synthesised (Life Technologies) using primers complementary to the original cDNA sequence (CTCTTCCTCATGGTCTAATACCTCCAC and TATCTCCAAATCAGTCCTTGCTTTCCC) from poly A+ mRNA obtained from U937 cells. After sequencing, this fragment was ligated onto the parent cDNA in a pBK-CMV vector (Stratagene) to produce the full length PI3K-C2α cDNA. Northern Blot Analysis Multiple human tissue poly A+ mRNA blots (Clontech) were hybridised with a 1.46 kb cDNA fragment corresponding to nucleotides 789-2249 of the PI3K- C2α coding sequence. The probe was labelled using [α 32 P] dCTP and random primers (Amersham). Hybridizations were performed in Express Hyb (Clontech) at 65°C for 16 hours. The blots were washed twice with 2xSSC, 0.05%SDS at room temperature and twice in IxSSC, 0.1 %SDS at 50°C. Bands were visualised by autoradiography. Plasmid Constructs and Expression of Recombinant Protein in Sf9 cells PI3K-C2α cDNA corresponding to amino acid residues 148-1686 was ligated in the pAcGex vector (44). Recombinant DNA (2μg) was transfected into Sf9 cells with 0.25μg BaculoGold DNA (Pharmingen) using Lipofectin (Gibco). Infections and amplifications (6xl0 5 cells/ml) of the viral stocks were performed for 48-60 hours or 96 hours respectively (45). After protein expression, cells were harvested and lysed in lOmM Tris/HCl (pH7.6), 5mM EDTA, 50mM NaCl, 30mM sodium pyrophosphate, 50mM NaF, lOOμ M Na 3 V0 4 , 1% Triton X-100 and ImM phenylmethysulphonyl fluoride (lysis buffer). The extracts were incubated with glutathione-Sepharose beads (Pharmacia) for 2-4 hours at 4°C. Bound proteins were recovered by centrifugation and after repeated washing with lysis buffer, the protein was transferred to storage buffer (50% ethyleneglycol, 5mM EDTA, 40mM Tris- HC1 ρH7.4, 5mM dithiothriotol, lOmM benzamidine) at -20 °C. Generation of Antisera to PI3K-C2α An amino-terminal fragment of the PI3K-C2α cDNA ( 1-101 lbp) was subcloned into pGex-2T vector. This plasmid was used to transform bacteria and the expression of a glutathione S -transferase (GST) fusion protein was induced. This protein was isolated using glutathione-sepharose beads and then eluted upon addition of excess glutathione. The GST fusion protein was used to immunise two rabbits, one of which produced antisera suitable for immunoprecipitation and western blotting PI3K-C2α from cell ly sates. Western blotting Various cell lines were extracted with Laemelli sample buffer and fractionated by SDS-PAGE. The proteins were then transferred onto PVDF membrane which was probed with the anti- PI3K-C2α antisera. After washing, the blots were incubated with goat -anti -rabbit HRP antibody and proteins were visualised by ECL ( Amersham). Subcellular Fractionation of PI3K-C2 The subcellular distribution of endogenous PI3K-C2α protein was examined by differential centrifugation of cell homogenates. Cells were disrupted either by dounce homogenisation or 10 passages through a 25 gauge needle in Tris/sucrose buffer ( 0.25M sucrose, 20mM Tris/ HC1 pH 7.4, ImM sodium orthovanadate, ImM PMSF, lOμg/ml leupeptin, 200 KlU/ml aprotonin, lμg/ml antipain, 400μg/ml benzamidine and lμg/ml pepstatin). The homogenate ( homog) was centrifuged at 3000g for 10 minutes to remove nuclei and unbroken cells. The supernatant( s/n) was spun at 18000g to obtain the plasma membrane fraction (pm) and the resultant supernatant centrifuged for an additional 30 minutes at 350000g. The pellet obtained was termed the low density microsomal fraction (LDM) and the supernatant cytosol ( cyt). All manipulations were performed at 4°C . Fractions were extracted in Laemelli sample buffer, analysed by SDS-PAGE and visualised by western blotting. Monkey Kidney Cos cells were transiently transfected with a 5' and 3' glu tagged PI3K-C2α construct ligated in a pMT-SM vector. These cells were used 48 hours following electroporation. For fractionation studies, proteins were visualised by a anti- glu tag monoclonal antibody following western blotting. These cells were also used to examine the localisation of the PI3K-C2α protein by confocal microscopy. For this purpose, electroporated cells were plated onto glass cover slips. After 48 hours, the cells were fixed, permeabilised and incubated with anti-glu tag monoclonal antibody for two hours. Cells were then washed and incubated with anti-mouse FITC coupled antibody.The staining pattern was then examined using a Zeiss confocal microscope. Assay of PI 3 -kinase Activity Typically, PI 3-kinase assays were performed in a total volume of 50μl containing 20mM Hepes pH7.4. lOOmM NaCl, O.lmM EGTA, 0.1% - mercaptoethanol, and 200μM phosphoinositide. After preincubating sonicated lipid with sample for 10 minutes, the reactions were initiated upon the addition of 2.5mM MgCl 2 , lOOmM ATP (0.2μCiγ[ 32 P] ATP). Assays were incubated at 30°C for 20 minutes and terminated with acidified chloroform:methanol. The extracted lipid products were analysed by thin layer chromatography using Silica gel 60 plates and chloroform:methanol:4M ammonium hydroxide (45:35:10) for assays examining phosphorylation of Ptdlns. When separations of Ptdlns 3P, Ptdlns (3,4) P 2 and PItdlns (3,4,5) P 3 was required, propan-1-ol: 2M acetic acid (65:35) was used. Phosphorylated lipids were visualised by either autoradiography or by phosphoimage analysis (Molecular Dynamics). Assays were linear with respect to time and enzyme addition. Characterisation of PI 3K-C2α Reaction Products by HPLC Phosphorylation of PI was performed using recombinant protein as described above. The reaction products were extracted in acidified chloroform :methanol and deacylated with methylamine (46). HPLC analysis of glycerophosphoinositols was performed using a Partisphere SAX column (Whatman International) and eluted using a linear gradient of 1M (NH 4 ) 2 HPO 4 (pH3.8) against water at 1 ml min "1 Radioactive peaks were detected using an in-line detector (Reeve Analytical). Results Cloning of PI3K-C2α Degenerate primers and mRNA from the human cell line U937 were used to produce a number of partial cDNAs by RT-PCR. One product of these reactions was found to be a novel cDNA which was then used to screen a λ Zap cDNA library made from U937 cells. Twenty seven positive clones selected from 3 x l0 6 plaques were obtained following tertiary screening. A 6.1kb clone was sequenced and found to contain an open reading frame of 4618 nucleotides which could encode a putative catalytic domain. Since no definitive 5' Kozak consensus sequence was found in this clone (24), RACE PCR was performed using cDNA from U937 cells. A 643 nucleotide extension to the original cDNA was generated. This cDNA fragment contained an ATG sequence which was in frame with the longest open reading frame of the parent clone and had an upstream stop codon. The RACE product was then ligated onto the parent clone to produce a composite cDNA of 5.1kb which could encode a protein of 1686 amino acid residues that would have a calculated molecular mass of 190 kDa (Figure 1). The protein which was termed PI3K-C2α, has an amino acid sequence which when optimally aligned, displays an overall sequence identity of 32.5% with the sequences of drosophila PI3K_68D and cpk (22,23) and 90.8% and 90.2% with those of the murine proteins mpl70 (16) and mcpk (22) respectively (Figure 2 upper panel). Two regions of amino acid sequence, HRI and HRII, define areas which have the greatest similarity to the sequences of other PI 3 -kinases. The putative catalytic domain (HRI) is defined by residues 1137-1398 of the PI3K- C2α or α protein. Within this region, the amino acid sequence of PI3K-C2α is 62% identical to that of PI3K_68D and cpk, 97% to mpl70 and 99.6% to mcpk (Figure 2 lower panel). When the HRI domain of PI3K-C2α is compared to that of pl lOα and Ptdlns 3-kinase, sequence identity falls to only 45% and 35% respectively amino acid residues 871-1020 of PI3K-C2α define a region termed the PIK domain (HR2) which is also present in other lipid kinases as well as TOR2 (25). The function of this domain is currently unknown The amino acid sequence of the carboxy terminal region of PI3K-C2α (residues 1549-1686) shows strong sequence homology to a domain originally identified as a Ca 2+ and phospholipid-binding module in protein kinase C, which is termed the C2 domain (13). In this region, the PI3K-C2 amino acid sequence is 96 % identical to that of the C2 domains identified in cpk-m and pl70, 39% identical to the C2 domain of PI3K 68D and cpk and 32% and 24% identical to the C2A and C2B domains of synaptotagmin respectively (Figure 2 lower panel). Within the amino terminal region, large insertions are necessary in the PI3K-C2α amino acid sequence to allow optimal alignment with that of Drosophila PI3K_68D and cpk. It is perhaps significant that the type II polyproline motif PPLPPR identified in PI3K_68D and cpk (residues 456-462) is absent in PI3K-C2α. Within this region however, numerous proline residues are evident. The amino terminus of PI3K-C2α lacks any clearly delineated regulatory domain. Interestingly, alignment of the two murine amino acid sequences with that of PI3K-C2α shows that the pi 70 protein lacks the first 176 amino residues of the longer murine mcpk sequence. The mcpk protein has a 28 amino acid residues deletion in this region (residues 275- 301 of the PI3K-C2αsequence) which is absent in both mpl 70 and PI3K-C2α (Figure 2, middle panel). The significance of these sequence differences requires further investigation. Tissue/Cell Expression of PI3K-C2α Northern blot analysis carried out using poly A+ RNA isolated from human tissue revealed that the cDNA encoding human PI3K-C2α hybridised to a 8kb species in the RNA from a wide variety of tissues (Figure 3). Highest levels of expression were found in the heart, placenta and ovary. The mRNA was only undetectable in the kidney. The size of the mRNA is consistent with the length of the full length cDNA. In testes, an additional smaller transcript of approximately 6.5 kb was also present and could have arisen from differential splicing. Western blots of cell lysates from a variety of cell-lines using the anti-PI3K- C2α antisera confirms the presence of the 190kDa polypeptide encoding PI3K- C2 in all cell-lines tested with the exception of the smooth muscle cell-line Rasmc, figure 7. Characterisation of Lipid Substrate Specificity To allow biochemical analysis of PI3K-C2α, a recombinant baculovirus was produced. The construct generated encoded a fusion protein which comprised the amino acid sequence of GST linked to residues 148-1686 of the PI3K-C2α protein. Sf9 cells were infected with the virus and after 2 days, the expressed protein was purified using glutathione-sepharose beads. The enzymatic activity and substrate specificity were investigated and compared to that of GST-pl 10a expressed in the same system. In the presence of Mg 2+ pl 10a was able to utilise Ptdlns, PtdIns(4)P and PtdIns(4,5)P 2 as substrates to produce PtdIns3P, Ptdlns(3,4) P 2 and PtdIns(3,4,5)P 3 respectively (Figure 4 upper panel). In contrast, PI3K-C2α was able to phosphorylate Ptdlns and PtdIns(4)P but could not use PtdIns(4,5)P 2 Like pi 10, the lipid kinase activity of PI3K-C2 displayed a cation dependence for Mg 2+ and was found to be inactive in the presence of Mn 2+ . This ion dependence of the enzyme activity of PI3K-C2α contrasts with that of the human Ptd Ins 3 -kinase which shows a preference the Mn 2+ (14). To confirm that PI3K-C2α could phosphorylate Ptdlns at the D-3 position on the inositol ring, anion exchange HPLC was performed upon the deacylated reaction products. A single peak of radioactive glycerolphosphate was obtained which co-eluted with the deacylated Ptdlns 3-P produced by the action of recombinant pi 10a upon Ptd Ins (Figure 4 lower panel). No additional products were observed confirming that PI3K-C2 specifically phosphorylates phosphatidylinositides at the D-3 position of their inositol ring. Sensitivity to Inhibitors of PI 3 -kinase Activity The compounds Wortmannin and LY294002 (2-(4-moφholinyι)-8-phenyl-4H- l-benzopyran-4-one) have been used extensively to assess the involvement of PI 3-kinase in many different physiological processes. To date, all cloned human PI 3 -kinases have been found to be sensitive to Wortmannin action at nanomolar concentrations. The effect of these inhibitors on the lipid kinase activity of PI3K-C2α was examined, using Ptdlns as a substrate, in the presence of increasing concentrations of each inhibitor. In agreement with previous studies, pi 10a activity was found to be sensitive to Wortmannin at low nM concentrations (IC 50 ^nM) with maximal attenuation of activity obtained at 1 OOnM (Figure 5 A). In contrast, the observed IC 50 using PI3K-C2α was 200nM with maximal inhibition only obtained using Wortmannin at lOμM. For LY294002, the IC 50 using pl lOα was 1.5mM and maximal inhibition was obtained at 300μM (Figure 5B). Again PI3K-C2α was less sensitive than pi 10a to the action of the inhibitor (IC 50 = 20μ M). The lipid kinase activity of PI3K- C2 α was maximally attenuated using 2mM LY294002. Subcellular Localisation of PI3K-C2α in Monkey Kidney Cos Cells To determine the subcellular location of PI3K-C2α, Monkey Kidney Cos cells were subjected to physical disruption followed by fractionation by differential centrifugation, figure 6. Figure 7 shows a western blot of various subcellular fractions prepared as described in materials and methods. A significant enrichment of PI3K-C2α polypeptide is shown in the LDM fraction when using the anti-amino terminus antisera, see figure 8 A. This enrichment is also reflected, although to a lesser extent, when using cell fractions prepared from electroporated Monkey Kidney Cos cells expressing glu tagged PI3K-C2α, see figure 8 B. The nature of the affinity of PI3K-C2α for microsomal membranes is currently unkown. Discussion In the present study the cloning and biochemical characterization of PI3K-C2α, a novel human PI 3-kinase of 190kDa is described. Based on the presence of a C-terminal C2 domain and the phospholipid substrate specificity of PI3K- C2α, this enzyme like Drosophila PI3K 68D (23), cpk (22) and the two murine PI 3-kinases mpl70 (16) and mcpk (22) can be defined as a class II PI 3-kinase (26) (Figure 2). The amino acid sequence of PI3K-C2α is 90.8% and 90.2% identical to that of two recently cloned murine PI 3 -kinases mp 170 (16) and mcpk respectively (22). This level of sequence identity suggests that PI3K-C2 is the human homologue of a single mouse PI3-kinase termed mpl 70 (27) or mcpk (28) which is encoded by the same gene. Despite the overall sequence identity between human PI3K-C2α and murine mpl 70 and mcpk, alignment of their N- termini shows that mpl 70 lacks the first 175 amino acid residues of both PI3K- C2α and cpk-m (Figure 2). In this region mcpk lacks 28 amino acid residues which are present in both PI3K-C2α and mpl 70. Analysis of the two murine cDNAs suggests that these differences in the proteins may be the result of differential splicing of a single gene. The putative catalytic domain (HRI) and the PIK domain (HR II) of PI3K-C2α are related to similar regions found in all Class I, II and III PI3-kinases. However, PI3K-C2α appears to lack any clear consensus sequences which would delineate other functional domains. For example, PI3K-C2α lacks the amino terminal motif present in pl lOα, pl lOβ and pl lOδ which mediates binding to p85 adaptors (29). Furthermore, PI3K-C2α does not contain the type II polyproline motif previously identified in PI3K_68D and cpk, although it does contain a large number of proline residues which might allow an interaction with SH3 domain-containing proteins through a non consensus binding motif (30). The class II PI3-kinases are in part characterised by their C-terminal C2 domain. C2 domains were originally identified in protein kinase C where they were shown to mediate Ca 2+ -dependent phospholipid binding (13). Subsequently, C2 domains, often occurring in tandem, have also been defined in a variety of other proteins including synaptotagmin, rabphillin 2 A and cytosolic phospholipase A2 (31). In these proteins the C2 domain may confer similar biochemical properties. Functional heterogeneity has however, been observed amongst isolated C2 domains despite their high degree of sequence similarity. In addition to phospholipid binding, Ca2+ stimulates an association between synaptotagmin and syntaxin through the first C2A domain (32). In contrast, the second C2B domain is inactive in these assays suggesting that its function is not regulated by intracellular Ca 2+ levels. Indeed, the second C2 domain of synaptotagmin was shown to display a Ca 2+ independent binding to clathrin AP2 and polyinositol phosphates (33, 34). Recent studies have since demonstrated however, that the second C2 domain of synaptotagmin can also respond in a Ca 2+ triggered manner mediating a dimerization event (35, 36). Studies using a GST-fusion protein of the PI3 K_68D C2 domain demonstrated that, like the second C2 domain of synaptotagmin, it was only able to bind acidic phospholipids in a cation independent manner (23). It will be of interest to determine if the biochemical properties of the PI3K-C2α domain are more similar to the first or the second synaptotagmin C2 domain. The biochemical analysis described here has shown that in vitro PI3K-C2α can phosphorylate both Ptd Ins and Ptd Ins (4)P in the D3 position of the inositol ring (Figure 4). These findings are consistent with the enzyme having a lipid specificity similar to that of PI3K 68D and cpk (23), (22). The substrate specificity of the mouse homologue has only been reported by Virbasius et al who concluded that Ptd Ins was the major lipid substrate of mpl 70 in vitro since they found that PtdIns(4)P was only very poorly phosphorylated by their enzyme (16). These results are somewhat surprising considering the degree of sequence identity between the catalytic domains of PI3K-C2α and mpl 70 (Figure 2). One explanation for this difference could be that Virbasius et al used a crude brain lipid extract substrate in contrast to the purified lipid preparations we have used in the analysis of substrate specificity (16). Although it could be argued that use of the crude extract may be more physiological, it does not allow for an accurate quantitative comparison of the lipids present in the two preparations. Under these circumstances, a comparative assessment of the efficiency with which an enzyme could utilize a particular lipid substrate cannot be made accurately. Furthermore, a crude lipid preparation may contain factors which influence the lipid kinase activity of the recombinant protein. The involvement of PI3-kinases in various processes of cell physiology has relied more and more on the use of the inhibitors Wortmannin and LY294002. Although initially described as an inhibitor of myosin light chain kinase at micromolar concentrations (37), Wortmannin was later shown to potently inhibit PDGF receptor-associated PI 3-kinase activity at 100 fold lower concentrations (2-5 nanomolar). Used in the low nanomolar range, Wortmannin was shown to block the generation of 3-phosphorylated lipids both in vitro and in whole cells such as murine fibroblasts (38). On the basis of such findings, Wortmannin began to be used extensively as a specific inhibitor of PI 3 -kinase activity thereby implicating the formation of 3 -phosphorylated lipids in a number of physiological responses. When the effect of Wortmannin on the lipid kinase activity of recombinant PI3K-C2α was examined we found that the concentrations of Wortmannin required to inhibit PI3K-C2α activity were more similar to those previously used to inhibit myosin light chain kinase (KX^HO- 200nM) (37, 39). Similarly, data presented using the mpl 70 enzyme suggests that it is also less sensitive to Wortmannin treatment than pl lOα (16). LY294002 is a structurally unrelated inhibitor of PI 3-kinase activity and PI3K- C2α is also less sensitive than pl lOα to this inhibitor. The difference in sensitivity between PI3K-C2α and pi 10a is however, only approximately one order of magnitude. The relevance of this differential sensitivity is unclear. Studies using pi 10a have shown that Wortmannin inactivates kinase activity by a covalent modification of Lys-802, a residue involved in the phosphate transfer reaction (40). This residue is present in all PI 3 -kinase family members including PI3K-C2α. Further molecular modelling and structural studies may elucidate the nature of this Wortmannin resistance. These results with PI3K- C2α contrast not only with those derived from studies of Class I and III human PI 3-kinases but also to those obtained with the Drosophila PI3K 68D which displays a sensitivity to Wortmannin which is similar to that of pi 1 Oα (23). The concentrations of both Wortmannin and LY294002 required to abolish PI3K- C2α activity are therefore likely to have precluded its inhibition in many experiments where PI 3-kinase activity has been studied. These findings may thus require many investigators to re-evaluate a possible involvement of PI3- kinase action in their physiological studies. Questions relating to the precise role PI3K-C2α plays in cells will consequently be hampered by the absence of suitable inhibitors of its lipid kinase activity REFERENCES 1. Schu, P. V., Takegawa, K., Fry, M. J., Stack, J. H., Waterfield, M. D., and Emr, S. D. (1993) Science 260, 88-92. 2. Davidson, H. W. (1995) J Cell Biol 130, 797-805. 3. Wennstrom, S., Hawkins, P., Cooke, F., Hara, K., Yonezawa, K., Kasuga, M., Jackson, T., Claesson Welsh, L., and Stephens, L. (1994) Curr Biol 4, 385-93. 4. Valius, M., and Kazlauskas, A. (1993) Cell 73, 321-34. 5. Cantley, L. C, Auger, K. R., Carpenter, C, Duckworth, B., Graziani, A., Kapeller, R., and Soltoff, S. (1991) Cell 64, 281-302. 6. Aagaard Tillery, K. M., and Jelinek, D. F. (1996) J Immunol 156, 4543- 54. 7. Jackson, T. R., Stephens, L. R., and Hawkins, P. T. (1992) J Biol Chem 267, 16627-36. 8. Auger, K. R., Serunian, L. A., Soltoff, S. P., Libby, P., and Cantley, L. C. (1989) Cell 57, 167-175. 9. Morgan, S. J., Smith, A. D., and Parker, P. J. (1990) Eur.J.Biochem. 191, 761 -767. 10. Hu, P., Mondino, A., Skolnik, E. Y., and Schlessinger, J. (1993) Mol Cell Biol 13, 7677-88. 11. Vanhaessebrock et al. (manuscript submitted, not yet published). 12. Stephens, L., Hawkins, P. T., Eguinoa, A., and Cooke, F. (1996) Phil.Trans.R.Soc.Lond. 351, 211-5. 13. Kaibuchi, K., Fukumoto, Y., Oku, N., Takai, Y., Arai, K., and Muramatsu, M. (1989) J Biol Chem 264, 13489-96. 14. Volinia, S., Dhand, R., Vanhaesebroeck, B., MacDougall, L. K., Stein, R., Zvelebil, M. J., Domin, J., Panaretou, C, and Waterfield, M. D. (1995) EMBO J 14, 3339-48. 15. Panaretou et al. (manuscript submitted, not yet published). 16. Virbasius, J. V., Guilherme, A., and Czech, M. P. (1996) J Biol Chem 271, 13304-13307 17. Ui, M. (1984) Trends Pharmacol. Sci. 5, 277-279. 18. Bagglollnl, M. et al. (1987) Exp. Cell Res. 169, 408-418. 19. Dewald, B., Thelen, M. and Bagglollnl, M. (1988) J Biol Chem. 263, 16179-16184. 20. Ui, M. Okada, T., Hazeki, K. and Hazeki, O. (1995) TIBS 20, 303-307 21. Kanal, F. et al, (1993) Biochem. Biophys. Res. Commun. 195, 762-768. 22. Molz, L., Chen, Y. W., Hirano, M., and Williams, L. T. (1996) J Biol Chem 271, 13892-99. 23. MacDougall, L. K., Domin, J., and Waterfield, M. D. (1995) Curr.Biol. 5, 1404-1415. 24. Kozak, M. (1991) J Biol Chem 266, 19867-70. 25. Flanagan, C. A., Schnieders, E. A., Emerick, A. W., Kunisawa, R., Admon, A., and Thorner, J. (1993) Science 262, 1444-8. 26. Domin, J. and Waterfield, M.D. (1997) FEBS Letts 410, 91-95. 27. Stephens, L., Smrcka, A., Cooke, F. T., Jackson, T. R., Stemweis, P. C, and Hawkins, P. T. (1994) Cell 77, 83-93. 28. Stoyanov, B., Volinia, S., Hanck, T., Rubio, I., Loubtchenkov, M., Malck, D., Stoyanova, S., Vanhaesebroeck, B., Dhand, R., Numberg, B., Gierschik, P., Seedorf, K., Hsuan, J. J., Waterfield, M. D., and Wetzker, R. (1995) Science 269, 690-693. 29. Dhand, R., Hara, K., Hiles, I., Bax, B., Gout, I., Panayotou, G., Fry, M. J., Yonezawa, K., Kasuga, M., and Waterfield, M. D. (1994) EMBO J. 13, 511-521. 30. Gout, I., Dhand, R., Hiles, I. D., Fry, M. J., Panayotou, G., Das, P., Truong, O., Totty, N. F., Hsuan, J., Booker, G. W., Campbell, I. D., and Waterfield, M. D. (1993) Cell 75, 25-36. 31. Ponting, C. P., and Parker, P. J. (1996) Protein Sci 5, 162-166. 32. Li, C, Davletov, B. A., and Sudhof, T. C. (1995) J Biol Chem 270, 24898-902. 33. Zhang, J. Z., Davletov, B. A., Sudhof, T. C, and Anderson, R. G. (1994) Cell 78, 751-60. 34. Fukuda, M., Kojima, T., Aruga, J., Niinobe, M., and Mikoshiba, K. (1995) J Biol Chem 270, 26523-7. 35. Chapman, E. R., An, S., Edwardson, M., and Jahn, R. (1996) J Biol Chem 271, 5844-5849. 36. Sugita, S., Hata, Y., and Sudhof, T. C. (1996) J Biol Chem 271, 1262-5. 37. Nakanishi, S., Kakita, S., Takahashi, I., Kawahara, K., Tsukuda, E., Sano, T., Yamada, K., Yoshida, M., Kase, H., Matsuda, Y., and et al. (1992) J Biol Chem 267, 2157-63. 38. Powis, G., Bonjouklian, R., Berggren, M. M., Gallegos, A., Abraham, R., Ashendel, C, Zalkow, L., Matter, W. F., Dodge, J., Grindey, G., and et al. (1994) Cancer Res 54, 2419-23. • 39. Yano, H., Nakanishi, S., Kimura, K., Hanai, N., Saitoh, Y., Fukui, Y., Nonomura, Y., and Matsuda, Y. (1993) J Biol Chem 268, 25846-56. 40. Wymann, W. P., Bulgarelli-Leva, G., Zvelebil, M. J., Pirola, L., Vanhaesebroeck, B., Waterfield, M. D., and Panayotou, G. (1996) Mol Cell Biol 16, 1722-33.

Claims: CLAIMS 1. An isolated nucleic acid molecule encoding the nucleotide sequence that is human PI3K-C2α, as represented in Figurel, or a fragment thereof, or a nucleic acid molecule that hybridizes under stringent conditions to the nucleotide sequence represented in Figure 1, or a fragment thereof. 2. An isolated nucleic molecule according to Claim 1 wherein said nucleic acid molecule is cDNA. 3. An isolated polypeptide encoding the amino acid sequence that is human PI3K-C2α as represented in Figure 1, or a fragment thereof. 4. An isolated polypeptide according to Claim 3 wherein said polypeptide is modified by deletion, substition or insertion of at least 1 amino acid. 5. An isolated polypeptide encoding a human class II kinase wherein said polypeptide is characterised by insensitivity to either or both of the PI3 kinase inhibitors Wortmannin or LY294002. 6. An isolated polypeptide according to Claims 3-5 wherein said polypeptide is characterised in that it lacks a binding site for the p85 adaptor protein. 7. An isolated polypeptide according to Claims 3 to 6 wherein said polypeptide is characterised by a lack of a polyproline motif found in the carboxyl terminal region of homologous class II PI3 kinases. 8. An isolated polypeptide according to Claims 3 to 7 wherein said polypeptide is characterised by a divergent amino terminus when compared to other class II PI3 kinases. 9. An isolated polypeptide according to Claims 3- 8 wherein said polypeptide is characterised in that it has a molecular weight of 190 kDa. 10. An isolated polypeptide according to Claims 3 to 9 wherein said polypeptide is characterised in that it catalyses the addition of phosphate to inositol to form Ptdlns and/or Ptdlns (4) P. 11. A recombinant vector including a nucleic acid molecule according to Claim 1 or Claim 2, which vector is adapted for expression of at least said nucleic acid molecule in prokaryotic or eukaryotic cells. 12. A recombinant vector according to Claim 11 wherein said vector is adapted so that said nucleic acid molecule is either inducibly, repressibly or constitutively expressed, said adaptation comprising the inclusion of at least one DNA promoter element necessary to confer inducible, repressible or constitutive expression, respectively, on said nucleic acid molecule. 13. A recombinant vector according to Claims 11 to 12 which is further adapted for cell/tissue specific expression of PI3K-C2α. 14. An antibody, or fragment thereof, directed against the polypeptide according to Claims 3 to 10. 15. An antibody according to Claim 14 wherein said antibody is a monoclonal antibody. 16. An antibody according to Claim 14 or 15 wherein said antibody is genetically engineered to contain a constant region of human immunoglobulin and a variable or active region of rodent immunoglobulin directed against the polypeptide of Claims 3-10. 17. A recombinant vector adapted for the expression of an in-frame fusion between a human immunoglobulin constant region, either light chain or heavy chain or both, and a variable region of a rodent immunoglobulin, either light chain or heavy chain or both, directed against the polypeptide of Claims 3-10. 18. A cell-line transformed or transfected with the recombinant vector according to Claim 17 for the manufacture of a humanised antibody against the polypeptide of Claims 3-10. 19. A method for the amplification of the isolated nucleic acid molecule of Claim lor the nucleic acid molecule encoding the polypeptide of Claim 5 wherein said method comprises a PCR reaction. 20. A method according to Claim 19 wherein said method comprises: using at least two primers adapted to hybridise to at least one selected part of said isolated nucleic acid molecule; providing conditions for amplifying and purifying at least one part of said nucleic acid molecule using said primers; and further, following amplification, said process comprises purifying the amplified product(s); and, optionally, isolating at least one of said amplified product. 21. DNA primers for use in the method according to Claims 19 or 20. 22. DNA primers according to Claim 21 wherein said primers have the following sequence, or a sequence that is similar or complementary thereto: 5 'GGNGA J 1 cGSA A T ' c T ' C TA A G CGNCAA Λ G GA 3 ' 5 ,A G GAA G TGICC G AA A G TC A G T ATTGAGTGAGAA 3 ' 23. An assay kit for identifying class II PI3 kinases and/or human PI3K- C2α kinase wherein said assay kit comprises an antibody according to Claims 14-16. 24. An assay kit according to Claim 23 wherein said assay kit is adapted for use as a diagnostic kit. 25. A method for identifying agonists or antagonists effective at enhancing or blocking the activity of the polypeptides of Claims 3-10 which method comprises the screening of ligands having an agonistic or antagonostic effect, respectively, on the activity of said polypeptides or parts thereof. 26. A method according to Claim 25 wherein said method comprises using a computer aided reconstruction of the 3 -dimensional structure and/or conventional laboratory techniques to predict the interaction between candidate ligands and selected domains of said polypeptides. 27. A pharmaceutical or veterinary composition comprising an agent identified using the method of Claims 25 or 26 for blocking the activity of class II PI3 kinase or PI3K-C2α. 28. A pharmaceutical or veterinary composition according to Claim 22 which includes a diluant, carrier or excipient. 29. Antisense oligonucleotide adapted to hybridise to the nucleic acid of Claims 1 or 2. 30. Antisense oligonucleotide according to Claim 29 wherein said oligonucleotide is modified as hereindescribe

Inventors: DOMIN JAN, WATERFIELD MICHAEL DEREK, DOMIN, JAN, WATERFIELD, MICHAEL, DEREK
Applicants: DOMIN JAN, LUDWIG INST CANCER RES, WATERFIELD MICHAEL DEREK, DOMIN, JAN, LUDWIG INSTITUTE FOR CANCER RESEARCH, WATERFIELD, MICHAEL, DEREK
Application year: 1998
Main classification: C12N15
IPC codes: C07K16, C12N9, C12N15, G01N33